news....usatoday, page-19

In reply to "fetid" I believe the following extract from his reference best describes the current position with Recell.

HEALTHPACT ACTION
"The evidence suggests that ReCell is capable of achieving similar outcomes to conventional treatment for burns, scar reconstruction and vitiligo. However, additional comparative studies with larger patient groups are necessary to determine the effectiveness of ReCell and to determine where it fits in current clinical treatment pathways. There is some agreement in the literature that ReCell is probably best utilised in cases with large affected areas where conventional grafting is difficult or requires cell culturing to cover the site, however no studies have been conducted to assess this. Additional data from the ongoing FDA trial would be useful. HealthPACT will note the development of this technology but further assessment by HealthPACT is not necessary at this time."

We are all waiting on the outcome of the FDA trial.